Taizhou city's Recbio ramps up moves into overseas markets

A bird's-eye view of Jiangsu Recbio Technology's plant. [Photo/WeChat account: weigg6666]

Jiangsu Recbio Technology Co – based in the Taizhou Medical High-tech Zone, Taizhou city, in East China's Jiangsu province – is actively expanding into markets to enable more consumers to benefit from its top homegrown products.

As a result, the new adjuvant recombinant REC610 herpes zoster vaccine developed by Recbio recently achieved positive trial results in the Philippines.

Research showed that local healthy participants aged 40 and above who received two doses of REC610 were generally safe and did well.

At present, Recbio has planned three new adjuvant production plants, one of which is fully completed, with the other two at the preliminary completion stage. Their products cover three types of mainstream adjuvants worldwide, with an annual peak production at full capacity set to top 100 million doses.

In terms of widening its overseas markets, Recbio founder Liu Yong said that taking the nine-valent human papillomavirus vaccine as an example, the group had formulated a detailed international market business development plan.

Liu added that his company would cooperate with the exports of finished products, semi-finished products and localized production in target international markets. The aim was to gradually achieve registration and listing in about 20 countries.

To date, Recbio has signed cooperation agreements with partners in the United Arab Emirates, India and the Philippines – bringing them high-quality nine-valent HPV vaccines.